Protalix Biotherapeutics, Inc. to Review CHMP Opinion for ELELYSO(TM)

Published: Jun 22, 2012

CARMIEL, Israel, June 22, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today the Company has scheduled a conference call and webcast for Friday, June 22, 2012 at 9:00 AM EDT to review the Committee for Medicinal Products for Human Use's (CHMP) opinion for taliglucerase alfa (ELELYSO™), an enzyme replacement therapy for the treatment of Gaucher disease.

Back to news